deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03380377

Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation

Sponsor: Stanley Jordan, MD

Conditions Antibody-mediated Rejection Kidney Transplant Rejection Kidney Transplant; Complications Transplant Glomerulopathy Transplant Glomerulopathy - Early Form Transplant Glomerulopathy - Late Form
Interventions Clazakizumab
Updated 15 times since 2018 Last updated: Apr 22, 2025 Started: Feb 21, 2018 Primary completion: Apr 16, 2024 Completion: Apr 16, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Antibody-mediated Rejection and Kidney Transplant Rejection, this trial is completed. The trial is conducted by Stanley Jordan, MD and has accumulated 15 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Apr 2020 · 12 months · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Apr 2022 · 12 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Apr 2024 · 12 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 15 months · monthly snapshot

Change History

15 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Apr 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Apr 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Apr 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Apr 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jan 2018 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Stanley Jordan, MD
Data source: Cedars-Sinai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations